Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2020-04-28 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
2019年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2019 Annual General Meeting (AGM) of 健帆生物科技集团股份有限公司. It details the procedures of the AGM, the qualifications of attendees, the agenda items discussed, and the voting results on various resolutions including the 2019 annual report, financial reports, profit distribution plan, remuneration plans, election of board members, and appointment of auditors. The document is focused on the AGM event itself, its legality, and the voting outcomes rather than the full annual report or financial statements. It is not the annual report (10-K) itself, nor a management discussion or earnings release. The document is a legal opinion related to the AGM and the voting results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is substantial and contains detailed voting results, supporting this classification rather than a brief announcement or a regulatory filing. Therefore, the best classification is DVA with high confidence.
2020-04-28 Chinese
2019年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2019 Annual General Meeting (AGM) of 健帆生物科技集团股份有限公司. It includes information about the meeting date, attendance, voting results on various agenda items including the 2019 annual report, financial reports, board and supervisory reports, profit distribution, remuneration plans, election of directors and supervisors, and legal opinions from lawyers witnessing the meeting. The document is not the annual report itself but the official announcement of the AGM resolutions and voting outcomes. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is sufficient and contains detailed voting results, confirming it is not a brief notice or a report publication announcement. Therefore, the correct classification is DVA with high confidence.
2020-04-28 Chinese
关于2016年限制性股票激励计划首次授予股票第三个解除限售期解除限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company regarding the achievement of conditions for the third release period of restricted stock under a 2016 stock incentive plan. It includes specifics about the number of shares, the performance conditions met, approvals by the board and supervisory committees, legal opinions, and financial advisor opinions. The content focuses on the lifting of restrictions on stock previously granted to employees and executives, including details on repurchases of unvested shares. This is not a full financial report, earnings release, or management discussion, but rather a formal announcement about stock incentive plan conditions being met and shares becoming unrestricted. It is not a proxy solicitation or voting result announcement, nor a remuneration report. The document is regulatory in nature, providing compliance and disclosure about stock incentive plan progress and related corporate actions. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into more specific categories like Share Issue/Capital Change or Director's Dealing, but relates to stock incentive plan disclosures and compliance.
2020-04-16 Chinese
第三届监事会第三十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of a company, specifically regarding stock incentive plans and stock option exercises. It includes voting results and references to compliance with company law and internal regulations. The document does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. It is a regulatory announcement about management decisions and approvals related to stock incentives. This fits best under Regulatory Filings (RNS) as it is a formal regulatory disclosure but not a full report or financial statement.
2020-04-16 Chinese
第三届董事会第四十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of the company, detailing decisions on stock incentive plans and stock option exercises. It includes voting results and references to related announcements published elsewhere. The document does not contain financial statements or detailed financial analysis, nor is it a transcript or presentation. It is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short and focused on board decisions, not a full report or regulatory filing. Therefore, the classification is MANG with high confidence.
2020-04-16 Chinese
上海荣正投资咨询股份有限公司关于公司2017年股票期权激励计划首次授予股票期权第二个行权期及预留授予第一个行权期行权条件成就之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2017 stock option incentive plan of the company 健帆生物科技集团股份有限公司. It details the fulfillment of exercise conditions for the second exercise period of the first grant and the first exercise period of the reserved grant of stock options. The report includes detailed explanations of approval procedures, performance assessments, exercise conditions, and the number and price of exercisable stock options. It is a standalone advisory report focusing on stock option incentive plan conditions and approvals, not a full annual or interim financial report, nor an earnings release or regulatory filing. It is not a simple announcement but a detailed report with substantive content and analysis related to stock option incentives. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit or advisory reports related to applied accounting principles and internal assessments, excluding full annual reports. Q1 2020
2020-04-16 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.